The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed on Thursday, dampening expectations for the closely watched drug.
A draft summary went online briefly on the WHO Web site and was first reported by the Financial Times and health news Web site Stat, which posted a screenshot.
However, Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying that the data showed a “potential benefit.”
Photo: AFP
The Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group, the summary said, adding that remdesivir was stopped early in 18 patients because of side effects.
The authors said that remdesivir was “not associated with a difference in time to clinical improvement” compared with the control.
After a month, 13.9 percent of the patients on remdesivir had died, compared with 12.8 percent of those in the control group. The difference is not statistically significant.
The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.
“We believe the post included inappropriate characterizations of the study,” a Gilead spokesman told reporters, adding that it was terminated early due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman said.
The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.
Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it.
Last week, Stat reported that it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated.
The US National Institutes of Health also reported it that had proven effective in a small experiment on monkeys.
Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly — as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA, and gets absorbed into the virus’ genome, which in turn stops the pathogen from replicating.
Anti-malarial drugs hydroxychloroquine and chloroquine have also been widely used on COVID-19 on a so-called “compassionate basis” pending results from large trials, with early studies decidedly mixed.
Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically engineered mice that were deliberately infected.
Separately in France, new research shows that nicotine could protect people from contracting COVID-19.
The findings came after researchers at a top Paris hospital examined 343 COVID-19 patients, as well as 139 people with the illness who had milder symptoms.
They found that a low number of them smoked, compared with smoking rates of about 35 percent in France’s general population.
“Among these patients, only 5 percent were smokers,” said Zahir Amoura, the study’s coauthor and a professor of internal medicine.
The research echoed similar findings published in the New England Journal of Medicine last month suggesting that 12.6 percent of 1,000 people infected in China were smokers.
That was a much lower figure than the number of regular smokers in China’s general population, about 26 percent, WHO data showed.
The theory is that nicotine could adhere to cell receptors, therefore blocking the novel coronavirus from entering cells and spreading in the body, said neurobiologist Jean-Pierre Changeux from France’s Pasteur Institute, who also coauthored the study.
The researchers are awaiting approval from health authorities to carry out further clinical trials.
The researchers are looking into whether nicotine could help to prevent “cytokine storms,” a rapid overreaction of the immune system that scientists think could play a key role in fatal COVID-19 cases.
However, with further research needed, experts are not encouraging people to pick up smoking or use nicotine patches as a protective measure against the virus.
“We must not forget the harmful effects of nicotine,” French Director-General for Health Jerome Salomon said.
“Those who do not smoke should absolutely not use nicotine substitutes,” which cause side effects and addiction, he said.
Kehinde Sanni spends his days smoothing out dents and repainting scratched bumpers in a modest autobody shop in Lagos. He has never left Nigeria, yet he speaks glowingly of Burkina Faso military leader Ibrahim Traore. “Nigeria needs someone like Ibrahim Traore of Burkina Faso. He is doing well for his country,” Sanni said. His admiration is shaped by a steady stream of viral videos, memes and social media posts — many misleading or outright false — portraying Traore as a fearless reformer who defied Western powers and reclaimed his country’s dignity. The Burkinabe strongman swept into power following a coup in September 2022
‘FRAGMENTING’: British politics have for a long time been dominated by the Labor Party and the Tories, but polls suggest that Reform now poses a significant challenge Hard-right upstarts Reform UK snatched a parliamentary seat from British Prime Minister Keir Starmer’s Labor Party yesterday in local elections that dealt a blow to the UK’s two establishment parties. Reform, led by anti-immigrant firebrand Nigel Farage, won the by-election in Runcorn and Helsby in northwest England by just six votes, as it picked up gains in other localities, including one mayoralty. The group’s strong showing continues momentum it built up at last year’s general election and appears to confirm a trend that the UK is entering an era of multi-party politics. “For the movement, for the party it’s a very, very big
ENTERTAINMENT: Rio officials have a history of organizing massive concerts on Copacabana Beach, with Madonna’s show drawing about 1.6 million fans last year Lady Gaga on Saturday night gave a free concert in front of 2 million fans who poured onto Copacabana Beach in Rio de Janeiro for the biggest show of her career. “Tonight, we’re making history... Thank you for making history with me,” Lady Gaga told a screaming crowd. The Mother Monster, as she is known, started the show at about 10:10pm local time with her 2011 song Bloody Mary. Cries of joy rose from the tightly packed fans who sang and danced shoulder-to-shoulder on the vast stretch of sand. Concert organizers said 2.1 million people attended the show. Lady Gaga
SUPPORT: The Australian prime minister promised to back Kyiv against Russia’s invasion, saying: ‘That’s my government’s position. It was yesterday. It still is’ Left-leaning Australian Prime Minister Anthony Albanese yesterday basked in his landslide election win, promising a “disciplined, orderly” government to confront cost-of-living pain and tariff turmoil. People clapped as the 62-year-old and his fiancee, Jodie Haydon, who visited his old inner Sydney haunt, Cafe Italia, surrounded by a crowd of jostling photographers and journalists. Albanese’s Labor Party is on course to win at least 83 seats in the 150-member parliament, partial results showed. Opposition leader Peter Dutton’s conservative Liberal-National coalition had just 38 seats, and other parties 12. Another 17 seats were still in doubt. “We will be a disciplined, orderly
RSS